Modernizing Care of Patients With BCC: Changes in Management Approaches

Target Audience
MDs, PAs, and NPs in Dermatology and Oncology

Program Overview
Utilize an interdisciplinary approach to identify patients with advanced BCC and apply expert guidance and clinical guidelines to determine the best treatment pathway for individual patients.

Identify patients with advanced BCC who have failed or cannot tolerate hedgehog inhibitor therapy and utilize an interdisciplinary approach to assess treatment options, including PD-1 inhibitors, and develop a plan to prevent/manage treatment-associated adverse events.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Identify patients for whom hedgehog inhibitor therapy may no longer be viable due to lack of response or adverse events
Apply expert guidance to augment guideline recommendations when determining treatment pathways in patients with advanced BCC
Summarize pivotal data on the efficacy and safety of PD-1 inhibitors, and their practical implications for treatment selection and AE prevention and management
Design an interdisciplinary approach to identifying patients with advanced BCC
Identify non-clinical patient needs to consider when assembling an interdisciplinary team to direct treatment and manage patients with advanced BCC